ID   CD47_HUMAN              Reviewed;         323 AA.
AC   Q08722; A8K198; D3DN59; Q53Y71; Q96A60;
DT   01-NOV-1995, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1995, sequence version 1.
DT   18-JUN-2025, entry version 211.
DE   RecName: Full=Leukocyte surface antigen CD47;
DE   AltName: Full=Antigenic surface determinant protein OA3;
DE   AltName: Full=Integrin-associated protein;
DE            Short=IAP;
DE   AltName: Full=Protein MER6;
DE   AltName: CD_antigen=CD47;
DE   Flags: Precursor;
GN   Name=CD47; Synonyms=MER6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM OA3-323).
RC   TISSUE=Ovary;
RX   PubMed=1394148;
RA   Campbell I.G., Freemont P.S., Foulkes W., Trowsdale J.;
RT   "An ovarian tumor marker with homology to vaccinia virus contains an IgV-
RT   like region and multiple transmembrane domains.";
RL   Cancer Res. 52:5416-5420(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM OA3-305), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TOPOLOGY.
RC   TISSUE=Myelomonocyte;
RX   PubMed=7691831; DOI=10.1083/jcb.123.2.485;
RA   Lindberg F.P., Gresham H.D., Schwarz E., Brown E.J.;
RT   "Molecular cloning of integrin-associated protein: an immunoglobulin family
RT   member with multiple membrane spanning domains implicated in alpha-v beta-
RT   3-dependent ligand binding.";
RL   J. Cell Biol. 123:485-496(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM OA3-305).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM OA3-323).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM OA3-305).
RC   TISSUE=Hippocampus, Leiomyosarcoma, and Ovarian adenocarcinoma;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 27-40; 60-75; 104-116; 169-197 AND 206-212, AND
RP   IDENTIFICATION AS CD47.
RC   TISSUE=Erythrocyte;
RX   PubMed=7998989; DOI=10.1042/bj3040525;
RA   Mawby W.J., Holmes C.H., Anstee D.J., Spring F.A., Tanner M.J.A.;
RT   "Isolation and characterization of CD47 glycoprotein: a multispanning
RT   membrane protein which is the same as integrin-associated protein (IAP) and
RT   the ovarian tumour marker OA3.";
RL   Biochem. J. 304:525-530(1994).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH THBS1.
RX   PubMed=8550562; DOI=10.1074/jbc.271.1.21;
RA   Gao A.G., Lindberg F.P., Finn M.B., Blystone S.D., Brown E.J.,
RA   Frazier W.A.;
RT   "Integrin-associated protein is a receptor for the C-terminal domain of
RT   thrombospondin.";
RL   J. Biol. Chem. 271:21-24(1996).
RN   [9]
RP   INTERACTION WITH UBQLN1 AND UBQLN2.
RX   PubMed=10549293; DOI=10.1016/s1097-2765(00)80212-9;
RA   Wu A.-L., Wang J., Zheleznyak A., Brown E.J.;
RT   "Ubiquitin-related proteins regulate interaction of vimentin intermediate
RT   filaments with the plasma membrane.";
RL   Mol. Cell 4:619-625(1999).
RN   [10]
RP   DISULFIDE BOND.
RX   PubMed=11454874; DOI=10.1074/jbc.m106107200;
RA   Rebres R.A., Vaz L.E., Green J.M., Brown E.J.;
RT   "Normal ligand binding and signaling by CD47 (integrin-associated protein)
RT   requires a long range disulfide bond between the extracellular and
RT   membrane-spanning domains.";
RL   J. Biol. Chem. 276:34607-34616(2001).
RN   [11]
RP   FUNCTION, AND INTERACTION WITH SIRPA.
RX   PubMed=11509594; DOI=10.4049/jimmunol.167.5.2547;
RA   Latour S., Tanaka H., Demeure C., Mateo V., Rubio M., Brown E.J.,
RA   Maliszewski C., Lindberg F.P., Oldenborg A., Ullrich A., Delespesse G.,
RA   Sarfati M.;
RT   "Bidirectional negative regulation of human T and dendritic cells by CD47
RT   and its cognate receptor signal-regulator protein-alpha: down-regulation of
RT   IL-12 responsiveness and inhibition of dendritic cell activation.";
RL   J. Immunol. 167:2547-2554(2001).
RN   [12]
RP   FUNCTION, AND INTERACTION WITH SIRPG.
RC   TISSUE=T-cell;
RX   PubMed=15383453; DOI=10.1182/blood-2004-07-2823;
RA   Piccio L., Vermi W., Boles K.S., Fuchs A., Strader C.A., Facchetti F.,
RA   Cella M., Colonna M.;
RT   "Adhesion of human T cells to antigen-presenting cells through SIRPbeta2-
RT   CD47 interaction costimulates T-cell proliferation.";
RL   Blood 105:2421-2427(2005).
RN   [13]
RP   INTERACTION WITH FAS/CD95.
RX   PubMed=15917238; DOI=10.1074/jbc.m500922200;
RA   Manna P.P., Dimitry J., Oldenborg P.A., Frazier W.A.;
RT   "CD47 augments Fas/CD95-mediated apoptosis.";
RL   J. Biol. Chem. 280:29637-29644(2005).
RN   [14]
RP   FUNCTION, AND INTERACTION WITH THBS1.
RX   PubMed=19004835; DOI=10.1074/jbc.m804860200;
RA   Isenberg J.S., Annis D.S., Pendrak M.L., Ptaszynska M., Frazier W.A.,
RA   Mosher D.F., Roberts D.D.;
RT   "Differential interactions of thrombospondin-1, -2, and -4 with CD47 and
RT   effects on cGMP signaling and ischemic injury responses.";
RL   J. Biol. Chem. 284:1116-1125(2009).
RN   [15]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-73 AND ASN-111.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of multiple
RT   enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [16]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-50 AND ASN-73.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-linked
RT   cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [17]
RP   INTERACTION WITH FIBRINOGEN.
RX   PubMed=22079249; DOI=10.1016/j.bbamem.2011.10.028;
RA   De Oliveira S., Vitorino de Almeida V., Calado A., Rosario H.S.,
RA   Saldanha C.;
RT   "Integrin-associated protein (CD47) is a putative mediator for soluble
RT   fibrinogen interaction with human red blood cells membrane.";
RL   Biochim. Biophys. Acta 1818:481-490(2012).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [19]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=27742621; DOI=10.1093/cvr/cvw218;
RA   Rogers N.M., Sharifi-Sanjani M., Yao M., Ghimire K., Bienes-Martinez R.,
RA   Mutchler S.M., Knupp H.E., Baust J., Novelli E.M., Ross M., St Croix C.,
RA   Kutten J.C., Czajka C.A., Sembrat J.C., Rojas M., Labrousse-Arias D.,
RA   Bachman T.N., Vanderpool R.R., Zuckerbraun B.S., Champion H.C., Mora A.L.,
RA   Straub A.C., Bilonick R.A., Calzada M.J., Isenberg J.S.;
RT   "TSP1-CD47 signaling is upregulated in clinical pulmonary hypertension and
RT   contributes to pulmonary arterial vasculopathy and dysfunction.";
RL   Cardiovasc. Res. 113:15-29(2017).
RN   [20]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=32679764; DOI=10.3390/cells9071695;
RA   Ghimire K., Li Y., Chiba T., Julovi S.M., Li J., Ross M.A., Straub A.C.,
RA   O'Connell P.J., Rueegg C., Pagano P.J., Isenberg J.S., Rogers N.M.;
RT   "CD47 Promotes Age-Associated Deterioration in Angiogenesis, Blood Flow and
RT   Glucose Homeostasis.";
RL   Cells 9:0-0(2020).
RN   [21]
RP   INTERACTION WITH MOSQUITO NEUTROPHIL-STIMULATING FACTOR 1, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=39121194; DOI=10.1126/sciimmunol.adk9872;
RA   Marin-Lopez A., Huck J.D., Esterly A.T., Azcutia V., Rosen C.,
RA   Garcia-Milian R., Sefik E., Vidal-Pedrola G., Raduwan H., Chen T.Y.,
RA   Arora G., Halene S., Shaw A.C., Palm N.W., Flavell R.A., Parkos C.A.,
RA   Thangamani S., Ring A.M., Fikrig E.;
RT   "The human CD47 checkpoint is targeted by an immunosuppressive Aedes
RT   aegypti salivary factor to enhance arboviral skin infectivity.";
RL   Sci. Immunol. 9:eadk9872-eadk9872(2024).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 19-136 IN COMPLEX WITH SIRPA,
RP   DISULFIDE BOND, GLYCOSYLATION AT ASN-23; ASN-50; ASN-73 AND ASN-111, AND
RP   PYROGLUTAMATE FORMATION AT GLN-19.
RX   PubMed=18657508; DOI=10.1016/j.molcel.2008.05.026;
RA   Hatherley D., Graham S.C., Turner J., Harlos K., Stuart D.I., Barclay A.N.;
RT   "Paired receptor specificity explained by structures of signal regulatory
RT   proteins alone and complexed with CD47.";
RL   Mol. Cell 31:266-277(2008).
CC   -!- FUNCTION: Adhesive protein that mediates cell-to-cell interactions
CC       (PubMed:11509594, PubMed:15383453). Acts as a receptor for
CC       thrombospondin THBS1 and as modulator of integrin signaling through the
CC       activation of heterotrimeric G proteins (PubMed:19004835,
CC       PubMed:7691831, PubMed:8550562). Involved in signal transduction,
CC       cardiovascular homeostasis, inflammation, apoptosis, angiogenesis,
CC       cellular self-renewal, and immunoregulation (PubMed:11509594,
CC       PubMed:15383453, PubMed:19004835, PubMed:27742621, PubMed:32679764,
CC       PubMed:7691831, PubMed:8550562). Plays a role in modulating pulmonary
CC       endothelin EDN1 signaling (PubMed:27742621). Modulates nitrous oxide
CC       (NO) signaling, in response to THBS1, hence playing a role as a pressor
CC       agent, supporting blood pressure (By similarity). Plays an important
CC       role in memory formation and synaptic plasticity in the hippocampus (By
CC       similarity). Receptor for SIRPA, binding to which prevents maturation
CC       of immature dendritic cells and inhibits cytokine production by mature
CC       dendritic cells (PubMed:11509594). Interaction with SIRPG mediates
CC       cell-cell adhesion, enhances superantigen-dependent T-cell-mediated
CC       proliferation and costimulates T-cell activation (PubMed:15383453).
CC       Positively modulates FAS-dependent apoptosis in T-cells, perhaps by
CC       enhancing FAS clustering (By similarity). Plays a role in suppressing
CC       angiogenesis and may be involved in metabolic dysregulation during
CC       normal aging (PubMed:32679764). In response to THBS1, negatively
CC       modulates wound healing (By similarity). Inhibits stem cell self-
CC       renewal, in response to THBS1, probably by regulation of the stem cell
CC       transcription factors POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 (By
CC       similarity). May play a role in membrane transport and/or integrin
CC       dependent signal transduction (PubMed:7691831). May prevent premature
CC       elimination of red blood cells (By similarity).
CC       {ECO:0000250|UniProtKB:P97829, ECO:0000250|UniProtKB:Q61735,
CC       ECO:0000269|PubMed:11509594, ECO:0000269|PubMed:15383453,
CC       ECO:0000269|PubMed:19004835, ECO:0000269|PubMed:27742621,
CC       ECO:0000269|PubMed:32679764, ECO:0000269|PubMed:7691831,
CC       ECO:0000269|PubMed:8550562}.
CC   -!- SUBUNIT: Monomer (PubMed:18657508). Interacts with THBS1 (via the C-
CC       terminal domain) (PubMed:19004835, PubMed:8550562). Interacts with
CC       SIRPA (PubMed:11509594). Interacts with FAS/CD95; interaction may be
CC       enhanced by functional activation (PubMed:15917238). Interacts with
CC       SIRPG, UBQLN1 and UBQLN2 (PubMed:10549293, PubMed:15383453,
CC       PubMed:18657508). May interact with fibrinogen (PubMed:22079249).
CC       Interacts with Aedes aegypti neutrophil-stimulating factor 1; the
CC       interaction results in inhibition of phagocytosis activity of
CC       macrophages (PubMed:39121194). {ECO:0000269|PubMed:10549293,
CC       ECO:0000269|PubMed:11509594, ECO:0000269|PubMed:15383453,
CC       ECO:0000269|PubMed:15917238, ECO:0000269|PubMed:18657508,
CC       ECO:0000269|PubMed:19004835, ECO:0000269|PubMed:22079249,
CC       ECO:0000269|PubMed:39121194, ECO:0000269|PubMed:8550562}.
CC   -!- INTERACTION:
CC       Q08722; P78324: SIRPA; NbExp=2; IntAct=EBI-1268321, EBI-745147;
CC       Q08722; Q9P1W8: SIRPG; NbExp=2; IntAct=EBI-1268321, EBI-1268284;
CC       Q08722; Q8N205: SYNE4; NbExp=3; IntAct=EBI-1268321, EBI-7131783;
CC       Q08722-3; P05067: APP; NbExp=3; IntAct=EBI-17263290, EBI-77613;
CC       Q08722-3; Q9H2K0: MTIF3; NbExp=3; IntAct=EBI-17263290, EBI-3923617;
CC       Q08722-3; P15941-11: MUC1; NbExp=3; IntAct=EBI-17263290, EBI-17263240;
CC       Q08722-3; P15151: PVR; NbExp=3; IntAct=EBI-17263290, EBI-3919694;
CC       Q08722-3; Q9NRX6: TMEM167B; NbExp=3; IntAct=EBI-17263290, EBI-17684533;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:39121194,
CC       ECO:0000269|PubMed:7691831}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:7691831}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=OA3-323;
CC         IsoId=Q08722-1; Sequence=Displayed;
CC       Name=OA3-293;
CC         IsoId=Q08722-2; Sequence=VSP_002535;
CC       Name=OA3-305;
CC         IsoId=Q08722-3; Sequence=VSP_002536, VSP_002537;
CC       Name=OA3-312;
CC         IsoId=Q08722-4; Sequence=VSP_002538;
CC   -!- TISSUE SPECIFICITY: Very broadly distributed on normal adult tissues,
CC       as well as ovarian tumors, being especially abundant in some epithelia
CC       and the brain. Macrophages (PubMed:39121194).
CC       {ECO:0000269|PubMed:39121194}.
CC   -!- INDUCTION: Induced in pulmonary artery and lung parenchyma following
CC       injury or stress (PubMed:27742621). Expression in arteries increases in
CC       normal aging (PubMed:32679764). {ECO:0000269|PubMed:27742621,
CC       ECO:0000269|PubMed:32679764}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X69398; CAA49196.1; -; mRNA.
DR   EMBL; Z25521; CAA80977.1; -; mRNA.
DR   EMBL; BT006907; AAP35553.1; -; mRNA.
DR   EMBL; AK289813; BAF82502.1; -; mRNA.
DR   EMBL; CH471052; EAW79733.1; -; Genomic_DNA.
DR   EMBL; CH471052; EAW79734.1; -; Genomic_DNA.
DR   EMBL; BC010016; AAH10016.1; -; mRNA.
DR   EMBL; BC012884; AAH12884.1; -; mRNA.
DR   EMBL; BC037306; AAH37306.1; -; mRNA.
DR   CCDS; CCDS43125.1; -. [Q08722-3]
DR   CCDS; CCDS43126.1; -. [Q08722-1]
DR   PIR; A48997; A48997.
DR   RefSeq; NP_001768.1; NM_001777.4. [Q08722-1]
DR   RefSeq; NP_942088.1; NM_198793.3. [Q08722-3]
DR   PDB; 2JJS; X-ray; 1.85 A; C/D=20-136.
DR   PDB; 2JJT; X-ray; 2.30 A; C/D=20-136.
DR   PDB; 2VSC; X-ray; 1.90 A; A/B/C/D=20-136.
DR   PDB; 4CMM; X-ray; 1.92 A; B=20-136.
DR   PDB; 4KJY; X-ray; 1.93 A; A/C=19-135.
DR   PDB; 5IWL; X-ray; 2.80 A; C/D=20-132.
DR   PDB; 5TZ2; X-ray; 2.30 A; C=19-141.
DR   PDB; 5TZT; X-ray; 2.89 A; C/D=20-141.
DR   PDB; 5TZU; X-ray; 2.10 A; C=19-141.
DR   PDB; 7MYZ; X-ray; 3.40 A; C/D=19-323.
DR   PDB; 7WN8; X-ray; 2.80 A; A/C=1-323.
DR   PDB; 7XJF; X-ray; 2.60 A; C=19-134.
DR   PDB; 7YGG; X-ray; 2.76 A; C/D=19-135.
DR   PDB; 8RP8; X-ray; 2.00 A; C/D=19-141.
DR   PDBsum; 2JJS; -.
DR   PDBsum; 2JJT; -.
DR   PDBsum; 2VSC; -.
DR   PDBsum; 4CMM; -.
DR   PDBsum; 4KJY; -.
DR   PDBsum; 5IWL; -.
DR   PDBsum; 5TZ2; -.
DR   PDBsum; 5TZT; -.
DR   PDBsum; 5TZU; -.
DR   PDBsum; 7MYZ; -.
DR   PDBsum; 7WN8; -.
DR   PDBsum; 7XJF; -.
DR   PDBsum; 7YGG; -.
DR   PDBsum; 8RP8; -.
DR   AlphaFoldDB; Q08722; -.
DR   SMR; Q08722; -.
DR   BioGRID; 107399; 63.
DR   CORUM; Q08722; -.
DR   DIP; DIP-39948N; -.
DR   FunCoup; Q08722; 652.
DR   IntAct; Q08722; 49.
DR   MINT; Q08722; -.
DR   STRING; 9606.ENSP00000355361; -.
DR   BindingDB; Q08722; -.
DR   ChEMBL; CHEMBL3714583; -.
DR   GuidetoPHARMACOLOGY; 2943; -.
DR   TCDB; 1.N.1.1.1; the osteoclast fusion complex (ofc) family.
DR   GlyConnect; 1456; 18 N-Linked glycans (1 site).
DR   GlyCosmos; Q08722; 6 sites, 20 glycans.
DR   GlyGen; Q08722; 7 sites, 84 N-linked glycans (4 sites), 1 O-linked glycan (1 site).
DR   iPTMnet; Q08722; -.
DR   PhosphoSitePlus; Q08722; -.
DR   SwissPalm; Q08722; -.
DR   BioMuta; CD47; -.
DR   DMDM; 1171879; -.
DR   CPTAC; CPTAC-5975; -.
DR   jPOST; Q08722; -.
DR   MassIVE; Q08722; -.
DR   PaxDb; 9606-ENSP00000355361; -.
DR   PeptideAtlas; Q08722; -.
DR   ProteomicsDB; 58643; -. [Q08722-1]
DR   ProteomicsDB; 58644; -. [Q08722-2]
DR   ProteomicsDB; 58645; -. [Q08722-3]
DR   ProteomicsDB; 58646; -. [Q08722-4]
DR   Pumba; Q08722; -.
DR   ABCD; Q08722; 62 sequenced antibodies.
DR   Antibodypedia; 4228; 1947 antibodies from 53 providers.
DR   CPTC; Q08722; 4 antibodies.
DR   DNASU; 961; -.
DR   Ensembl; ENST00000355354.13; ENSP00000347512.7; ENSG00000196776.17. [Q08722-3]
DR   Ensembl; ENST00000361309.6; ENSP00000355361.5; ENSG00000196776.17. [Q08722-1]
DR   GeneID; 961; -.
DR   KEGG; hsa:961; -.
DR   MANE-Select; ENST00000361309.6; ENSP00000355361.5; NM_001777.4; NP_001768.1.
DR   UCSC; uc003dwt.2; human. [Q08722-1]
DR   AGR; HGNC:1682; -.
DR   CTD; 961; -.
DR   DisGeNET; 961; -.
DR   GeneCards; CD47; -.
DR   HGNC; HGNC:1682; CD47.
DR   HPA; ENSG00000196776; Low tissue specificity.
DR   MIM; 601028; gene.
DR   OpenTargets; ENSG00000196776; -.
DR   VEuPathDB; HostDB:ENSG00000196776; -.
DR   eggNOG; ENOG502RYTQ; Eukaryota.
DR   GeneTree; ENSGT00390000007697; -.
DR   HOGENOM; CLU_860392_0_0_1; -.
DR   InParanoid; Q08722; -.
DR   OMA; CISECTP; -.
DR   OrthoDB; 9447188at2759; -.
DR   PAN-GO; Q08722; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; Q08722; -.
DR   PathwayCommons; Q08722; -.
DR   Reactome; R-HSA-202733; Cell surface interactions at the vascular wall.
DR   Reactome; R-HSA-216083; Integrin cell surface interactions.
DR   Reactome; R-HSA-391160; Signal regulatory protein family interactions.
DR   Reactome; R-HSA-6798695; Neutrophil degranulation.
DR   SignaLink; Q08722; -.
DR   SIGNOR; Q08722; -.
DR   BioGRID-ORCS; 961; 12 hits in 1163 CRISPR screens.
DR   ChiTaRS; CD47; human.
DR   EvolutionaryTrace; Q08722; -.
DR   GeneWiki; CD47; -.
DR   GenomeRNAi; 961; -.
DR   Pharos; Q08722; Tchem.
DR   PRO; PR:Q08722; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   RNAct; Q08722; protein.
DR   Bgee; ENSG00000196776; Expressed in gingival epithelium and 206 other cell types or tissues.
DR   ExpressionAtlas; Q08722; baseline and differential.
DR   GO; GO:0009986; C:cell surface; IDA:ARUK-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0035579; C:specific granule membrane; TAS:Reactome.
DR   GO; GO:0070821; C:tertiary granule membrane; TAS:Reactome.
DR   GO; GO:0098632; F:cell-cell adhesion mediator activity; IPI:ARUK-UCL.
DR   GO; GO:0070051; F:fibrinogen binding; IDA:UniProtKB.
DR   GO; GO:0086080; F:protein binding involved in heterotypic cell-cell adhesion; ISS:ARUK-UCL.
DR   GO; GO:0070053; F:thrombospondin receptor activity; IDA:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:1904669; P:ATP export; IDA:ARUK-UCL.
DR   GO; GO:0016477; P:cell migration; ISS:ARUK-UCL.
DR   GO; GO:0071347; P:cellular response to interleukin-1; ISS:ARUK-UCL.
DR   GO; GO:0071349; P:cellular response to interleukin-12; IMP:ARUK-UCL.
DR   GO; GO:0071346; P:cellular response to type II interferon; ISS:ARUK-UCL.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0007229; P:integrin-mediated signaling pathway; TAS:ProtInc.
DR   GO; GO:0050765; P:negative regulation of phagocytosis; ISS:ARUK-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IDA:UniProtKB.
DR   GO; GO:0022409; P:positive regulation of cell-cell adhesion; IDA:UniProtKB.
DR   GO; GO:0050729; P:positive regulation of inflammatory response; IBA:GO_Central.
DR   GO; GO:2000439; P:positive regulation of monocyte extravasation; ISS:ARUK-UCL.
DR   GO; GO:0050766; P:positive regulation of phagocytosis; IBA:GO_Central.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; ISS:ARUK-UCL.
DR   GO; GO:0050870; P:positive regulation of T cell activation; IDA:UniProtKB.
DR   GO; GO:0060368; P:regulation of Fc receptor mediated stimulatory signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0032653; P:regulation of interleukin-10 production; IMP:ARUK-UCL.
DR   GO; GO:0032655; P:regulation of interleukin-12 production; IMP:ARUK-UCL.
DR   GO; GO:0032675; P:regulation of interleukin-6 production; IMP:ARUK-UCL.
DR   GO; GO:0045428; P:regulation of nitric oxide biosynthetic process; ISS:ARUK-UCL.
DR   GO; GO:0032680; P:regulation of tumor necrosis factor production; IMP:ARUK-UCL.
DR   GO; GO:0032649; P:regulation of type II interferon production; IMP:ARUK-UCL.
DR   CDD; cd16090; IgV_CD47; 1.
DR   FunFam; 2.60.40.10:FF:000521; leukocyte surface antigen CD47; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 1.
DR   InterPro; IPR006704; CD47.
DR   InterPro; IPR013147; CD47-like_TM.
DR   InterPro; IPR013270; CD47_Vset.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR037805; IgV_CD47.
DR   PANTHER; PTHR10613; LEUKOCYTE SURFACE ANTIGEN CD47; 1.
DR   PANTHER; PTHR10613:SF0; LEUKOCYTE SURFACE ANTIGEN CD47; 1.
DR   Pfam; PF04549; CD47; 1.
DR   Pfam; PF08204; V-set_CD47; 1.
DR   SUPFAM; SSF48726; Immunoglobulin; 1.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   neXtProt; NX_Q08722; -.
DR   PharmGKB; PA26222; -.
DR   TreeFam; TF336026; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Angiogenesis; Apoptosis; Cell adhesion;
KW   Cell membrane; Direct protein sequencing; Disulfide bond; Glycoprotein;
KW   Immunoglobulin domain; Inflammatory response; Membrane; Phosphoprotein;
KW   Proteomics identification; Pyrrolidone carboxylic acid; Reference proteome;
KW   Signal; Transmembrane; Transmembrane helix.
FT   SIGNAL          1..18
FT                   /evidence="ECO:0000255"
FT   CHAIN           19..323
FT                   /note="Leukocyte surface antigen CD47"
FT                   /id="PRO_0000014880"
FT   TOPO_DOM        19..141
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        142..162
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        163..176
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        177..197
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        198..207
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        208..228
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        229..235
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        236..256
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        257..268
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        269..289
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        290..323
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          19..127
FT                   /note="Ig-like V-type"
FT   MOD_RES         19
FT                   /note="Pyrrolidone carboxylic acid"
FT                   /evidence="ECO:0000269|PubMed:18657508"
FT   MOD_RES         89
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P97829"
FT   CARBOHYD        23
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18657508"
FT   CARBOHYD        34
FT                   /note="N-linked (GlcNAc...) asparagine"
FT   CARBOHYD        50
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18657508,
FT                   ECO:0000269|PubMed:19349973"
FT   CARBOHYD        73
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18657508,
FT                   ECO:0000269|PubMed:19159218, ECO:0000269|PubMed:19349973"
FT   CARBOHYD        111
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:18657508,
FT                   ECO:0000269|PubMed:19159218"
FT   CARBOHYD        206
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        33..263
FT                   /evidence="ECO:0000269|PubMed:11454874"
FT   DISULFID        41..114
FT                   /evidence="ECO:0000269|PubMed:18657508"
FT   VAR_SEQ         293..323
FT                   /note="Missing (in isoform OA3-293)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002535"
FT   VAR_SEQ         304..305
FT                   /note="KA -> NN (in isoform OA3-305)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7691831, ECO:0000303|Ref.3"
FT                   /id="VSP_002536"
FT   VAR_SEQ         306..323
FT                   /note="Missing (in isoform OA3-305)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:7691831, ECO:0000303|Ref.3"
FT                   /id="VSP_002537"
FT   VAR_SEQ         312..323
FT                   /note="Missing (in isoform OA3-312)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_002538"
FT   STRAND          26..30
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          35..39
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          42..45
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   HELIX           51..53
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          54..60
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          63..69
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   HELIX           70..72
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          74..76
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   HELIX           79..81
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   HELIX           88..93
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          98..101
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   HELIX           102..106
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          110..118
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   STRAND          121..131
FT                   /evidence="ECO:0007829|PDB:2JJS"
FT   TURN            139..143
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   HELIX           144..164
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   HELIX           178..196
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   STRAND          197..202
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   HELIX           204..224
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   HELIX           238..253
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   TURN            254..260
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   STRAND          261..264
FT                   /evidence="ECO:0007829|PDB:7MYZ"
FT   HELIX           268..292
FT                   /evidence="ECO:0007829|PDB:7MYZ"
SQ   SEQUENCE   323 AA;  35214 MW;  5D20730A2632D550 CRC64;
     MWPLVAALLL GSACCGSAQL LFNKTKSVEF TFCNDTVVIP CFVTNMEAQN TTEVYVKWKF
     KGRDIYTFDG ALNKSTVPTD FSSAKIEVSQ LLKGDASLKM DKSDAVSHTG NYTCEVTELT
     REGETIIELK YRVVSWFSPN ENILIVIFPI FAILLFWGQF GIKTLKYRSG GMDEKTIALL
     VAGLVITVIV IVGAILFVPG EYSLKNATGL GLIVTSTGIL ILLHYYVFST AIGLTSFVIA
     ILVIQVIAYI LAVVGLSLCI AACIPMHGPL LISGLSILAL AQLLGLVYMK FVASNQKTIQ
     PPRKAVEEPL NAFKESKGMM NDE
//
